Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalent Vaccine + OPT-821 + β-glucan +/- GM-CSF for High-risk Neuroblastoma
NCT04936529Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2021
- Primary completion
- Jun 2027
- Modality
- Therapeutic Vaccines, Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of adagloxad simolenin, beta-D-glucan and sargramostim in neuroblastoma (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Effect of GM-CSF on anti-GD2 antibody titers at 32 weeks. Started Aug 2021; status: recruiting.
02
Drugs
adagloxad simoleninbeta-D-glucansargramostim
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT04936529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04936529.